Hep C and Lymphoma
Hepatitis C, often known as HCV or hep C, is a chronic disease that targets the liver and results in inflammation of the liver. When someone comes in contact with the blood of an individual who has hepatitis C, it spreads.
According to the Centers for Disease Control and Prevention, over 2.4 million Americans have HCV. In the US, 50% of instances of liver cancer are attributed to chronic HCV infection.
Hepatitis C treatment can lower the risk of consequences such liver damage, cirrhosis, and liver cancer. Actually, with the right care, the majority of hep C cases can be cured in a few months, and a successful course of treatment can lower the risk of developing liver cancer by 75%.
Yet untreated chronic hepatitis C raises the risk of various cancers, including non-lymphoma Hodgkin’s (NHL).
The early treatment of HCV may reduce the chance of getting NHL, particularly in adults under the age of 65, according to a 2020 study that tracked 10,714 individuals with chronic hepatitis C for over 4 years. More study is necessary, though.